| IGMS Stock | | | USD 1.36 0.02 1.49% |
President
Mary MD is President Unit of IGM Biosciences
| Age | 60 |
| Address | 325 East Middlefield Road, Mountain View, CA, United States, 94043 |
| Phone | 650 965 7873 |
| Web | https://igmbio.com |
IGM Biosciences Management Efficiency
The company has return on total asset
(ROA) of
(0.3738) % which means that it has lost $0.3738 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity
(ROE) of
(1.3211) %, meaning that it created substantial loss on money invested by shareholders. IGM Biosciences' management efficiency ratios could be used to measure how well IGM Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.
Return On Tangible Assets is likely to drop to -0.55 in 2025.
Return On Capital Employed is likely to drop to -0.65 in 2025. At this time, IGM Biosciences'
Non Current Assets Total are comparatively stable compared to the past year.
Non Currrent Assets Other is likely to gain to about 2.2
M in 2025, whereas
Net Tangible Assets are likely to drop slightly above 192.1
M in 2025.
IGM Biosciences currently holds 40.51
M in liabilities with Debt to Equity
(D/E) ratio of 0.09, which may suggest the company is not taking enough advantage from borrowing. IGM Biosciences has a current ratio of 10.57, suggesting that it is
liquid enough and is able to pay its financial obligations when due. Note, when we think about IGM Biosciences' use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 1 records | PRESIDENT Age |
| Pratik Shah | Design Therapeutics | 55 |
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. IGM Biosciences, Inc. was incorporated in 1993 and is headquartered in Mountain View, California. Igm Biosciences operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 242 people. IGM Biosciences (IGMS) is traded on NASDAQ Exchange in USA. It is located in 325 East Middlefield Road, Mountain View, CA, United States, 94043 and employs 198 people. IGM Biosciences is listed under Biotechnology category by Fama And French industry classification.
Management Performance
IGM Biosciences Leadership Team
Elected by the shareholders, the IGM Biosciences' board of directors comprises two types of representatives: IGM Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of IGM. The board's role is to monitor IGM Biosciences' management team and ensure that shareholders' interests are well served. IGM Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, IGM Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| TS Harigopal, Senior Operations | |
| Faraz Siddiqui, Senior Operations | |
| Angus Sinclair, Senior ImmunoOncology | |
| Elizabeth JD, Senior Property | |
| Elaine Sapinoso, Senior Quality | |
| Misbah CPA, Chief Officer | |
| Lisa Decker, Chief Officer | |
| Paul JD, Senior Affairs | |
| Steven Weber, Corporate VP | |
| Shinyu MD, Consultant | |
| Bruce Keyt, Chief Officer | |
| Fred JD, President CEO | |
| Suzette Tauber, Chief Officer | |
| Misbah Tahir, Chief Officer | |
| Paul Graffagnino, Senior Affairs | |
| FACP MD, Chief Officer | |
| Marvin Peterson, Executive Manufacturing | |
| Mary MD, President Unit | |
IGM Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is IGM Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Additional Tools for IGM Stock Analysis
When running IGM Biosciences' price analysis, check to
measure IGM Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy IGM Biosciences is operating at the current time. Most of IGM Biosciences' value examination focuses on studying past and present price action to
predict the probability of IGM Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move IGM Biosciences' price. Additionally, you may evaluate how the addition of IGM Biosciences to your portfolios can decrease your overall portfolio volatility.